JNJ-64565111
Sponsors
Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.
Conditions
Diabetes Mellitus, Type 2HealthyKidney Failure, ChronicObesity
Phase 1
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)
TerminatedNCT02862431
Start: 2016-07-12End: 2016-12-05Updated: 2025-04-27
A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus
CompletedNCT03235219
Start: 2017-08-01End: 2018-02-19Updated: 2025-04-27
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
CompletedNCT03546205
Start: 2018-06-06End: 2018-12-17Updated: 2025-04-27
A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose
CompletedNCT03586843
Start: 2018-06-29End: 2019-03-17Updated: 2019-04-16
A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)
CompletedNCT03606057
Start: 2018-07-13End: 2019-02-28Updated: 2020-03-03
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants
TerminatedNCT03618160
Start: 2018-08-06End: 2019-06-21Updated: 2025-02-03